Apoptosis and apoptosis-related proteins (Fas, Fas ligand, Blc-2, p53) in lymphoid elements of human ovarian tumors

Different types of lymphocytes have different roles in tumor suppression. Thus, their expression of apoptosis-related proteins (ARP - Fas and Fas ligand, bcl-2, p53) in lymphocytes and their apoptosis were analyzed immunohistochemically in ovarian tumors of different grades. Ovaries without oncologic disorders had few lymphocytes, mainly T cells, and no ARP. Benign cysts presented features of weak immune reaction: small lymphoid infiltration and few lymphocytes. The ARP were present in 13.7% to 23.5% of the lymphocytes, and apoptosis was rare. In borderline tumors, expansion of lymphoid infiltrates and increased density of lymphocytes resulted in a tenfold rise in total lymphocytes, reflecting intensification of the immune response. Most lymphocytes were T cells (92%) predominated by CD8+ cells that were in direct contact with tumor epithelial cells. ARP species were found in 47% to 65% of the lymphocytes, and apoptosis in 2.2%. In carcinomas with ligh lymphoid infiltration, lymphocytes were 2.5 times more abundant, and the apoptotic index as well as the number of CD20+ and CD25+ lymphocytes rose sharply, whereas bcl-2 positive lymphocytes decreased to 8% of their number in borderline tumors. In carcinomas with low lymphoid infiltration, the total lymphocyte count decreased eightfold compared to carcinomas with high lymphoid infiltration, reflecting the deep subcompensation of the lymphoid system. Few p53-positive lymphocytes were found in the carcinomas. In conclusion, we found a positive correlation between apoptosis and the numbers of CD4+ or CD8+ lymphocytes in epithelial ovarian tumors. This correlation could reflect the antitumor activity of T cells. However, the high expression of ARP studied by immune cells at the vicinity of the tumor ARP reveals the lymphoid vulnerability to apoptosis, resulting in devastation of the lymphoid tissue, and consequently in tumor progression.

Apoptosis; bcl-2; Fas and Fas ligand; Lymphocytes; Ovarian epithelial tumors

[1] Schroder W., Vering A., Stegmuller M., Strolmeier R.: "Lymphocyte subsets in patients with ovarian and breast cancer". Eur. J. Oneal., 1997, 18, 474.

[2] Schondorf T., Engel H., Kurbacher C. M., Brenne U., Kolhagen H., Gobring U. J., Scharl A., Mallmann P.: "Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients". J. Soc. Gynecol. Invest., 1998, 5, 102.

[3] Drozdzik M., Qian C., Lasarte J. J., Bilbao R., Prieto J.: "Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL)". Gene Therapy, 1998, 5, 1622.

[4] Nagata S.: "Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model". H. Human Genet.,1998, 43, 2.

[5] Ben-Hur H., Gurevich P., Huszar M., Berman V., Ben-Arie A., Tendler Y. et al.: "Expression of apoptosis and apoptosis- related proteins in human ovarian tumors of different histologic grades: immunohistochemical and morphometric studies". Eur. J. Gynaecol. Oneal., 1999, 20, 249.

[6] Gurevich P., Czernobilsky B., Ben-Hur H., Nyska A., Zuckerman A., Zusman I.: "Pathology of lymphoid organs in low-birth weight human fetuses subjected to antigeninduced influences: a morphological and morphometric study". Pediatric Pathol., 1994, 14, 679.

[7] Wong P. Y., Staren E. D., Tereshkova N., Braun D. P.: "Functional analysis of tumor-infiltrating leukocytes in breast cancer patients". J. Surg. Res., 1998, 76, 95.

[8] McMillan D. C., Fyffe G. D., Wotherspoon H. A., Cooke T. G., Mcardle C. S.: "P rospective study of circulating T lymphocyte subpopulations and disease progression in colorectal cancer". Dis. Colon Rectum., 1997, 40, 1068.

[9] Hartveit F.: "Breast cancer: poor short-term prognosis in cases with moderate lymphocyte infiltration at the tumour edge: a preliminary report". Oncol. Rep., 1998, 5, 423.

[10] Stephens M., Lim K., Stephens P., Thomas D. W., Lim S. H.: "Molecular characterisation of tumour infiltrating lymphocytes in oral squamous cell carcinoma". Cancer Immun. Immunother., 1998, 46, 34.

[11] Yannelli J. R., McConnell S., P arker L., Nishimura M., Robbins P., Yang J. et al.: "Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: comparison of functional reactivity and melanoma antigen recognition". J. Immunother., 1995, 4, 263.

[12] Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura A., Ohtani H.: "CDS+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer". Cancer Res., 1998, 58, 3491.

[13] Grekou A. N., Toliou T., Stravoravdi P., P atakiouta F., Tsoukalas T., Pinakidis M., Keramidas G.: "Correlation of apoptosis with the distribution and composition of lymphocytic infiltrate in human breast carcinomas". Anticancer Res., 1996, 16, 3991.

[14] Yang E., Korsmeyer S. J.: "Molecular thanatopsis: a discourse on the bcl-2 family and cell death". Blood, 1996, 88, 386.

[15] Green D.R., Ware C. F.: "Fas-ligand: privilege and peril". Proc. Natl. Acad. Sci. USA, 1997, 94, 598.

[16] Niehans G. A., Brunner T., Frizelle S. P., Liston J. C., Salemo C. T., Knapp D. J. et al.: "Human lung carcinomas express Fas ligand". Cancer Res., 1997, 57, 1007.

[17] Abe M., Kitsuki H., Saruwatari S., Asoh H., Sakurada T., Kuwata H. et al.: "Cancer cells isolated from malignant pleural and peritoneal effusions inhibit phospholipase A2 activity in human polymorphonuclear leukocytes". Cancer Lett., 1997, 121, 155.

[18] Mantovani G., Maccio A., Massa E., Lai P., Manca G., Mudu C. et al.: "Relationships between Fas expression, activation molecule CD25, and functional activity of tumorassociated lymphomonocytes from neoplastic effusions". Oncol. Rep., 1998, 6, 235.

[19] O'Connell J., O'Sullivan G. C., Collins J. K.: "The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand". J. Exp. Med., 1996, 184, 1075.

[20] Hahna M., Rimoldi D., Schreter M., Romero P., Schreier M., French L. E. et al.: "Melanoma cell expression of Fas (Apo-l/CD95) ligand: implications for tumor immune escape". Science, 1996, 274, 1363.

[21] O'Sullivan C., Lewis C.: "Tumour-associated leukocytes: friends or foes in breast carcinoma". J. Pathol., 1994, 172, 229.

[22] Berke G.: "The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects". Annual Rev. Immunol., 1994, 12, 735.